International (Australia, Brazil, Canada, Japan, United States)

MDSAP Audit Approach (MDSAP AU P0002)

83 controls. 0 other frameworks in our corpus share controls with it. Here is all of it, and how much of it you are already doing.

Page built . This page is derived from the framework corpus, which changes when the corpus is extended rather than daily.

83 controls 0 frameworks share controls with it International (Australia, Brazil, Canada, Japan, United States) verified against its source document

Every control below is one this framework asks for. The right hand column counts how many other frameworks in our corpus carry the same control, which is the difference between doing this work once and doing it again for the next standard.

There is no implementation kit for this framework yet. The control list and the overlap above are free and complete.

What you already have

Frameworks whose controls overlap this one, most first. If you run any of them, the count is roughly what you have already evidenced.

No measured overlap with another framework in the corpus.

Every control

CodeControlAlso in
A1-techdocMaintain technical documentation (medical device file and design files) that evidences regulatory compliance, keep it current, and for Australia meet the minimum Essential Principl0
A2-sterileControl every process contributing to sterility through the QMS, with validated and revalidated processes, routine monitoring, batch records, designated lot release and controlled 0
A3-A5Annex 3 reporting timeframes, Annex 4 Japan QMS Ordinance tables, Annex 5 acceptable exclusions, and the MDO eligibility pilot (MDSAP AU P0038.002)0
C1-T1Plan, document and maintain the QMS with a risk-based approach to process control, manage QMS changes and keep a quality manual0
C1-T10Distribute or offer devices only into markets where they hold the required marketing authorization, and license and label private-label devices for Canada correctly0
C1-T11Top management demonstrates commitment to an effective QMS and communicates its effectiveness, as judged across management, measurement and improvement, design, production and purc0
C1-T2Appoint and document a management representative responsible for QMS effectiveness, reporting to top management and promoting regulatory awareness0
C1-T3Set a quality policy and measurable quality objectives at relevant functions and levels, consistent with the policy, and act to achieve them0
C1-T4Define the organisational structure, responsibilities and authorities, and provide the people, infrastructure, competence and training needed to design and make devices as planned0
C1-T5Document the extent of outsourcing and the controls over outsourced processes, keep the supplier list current, and divide regulatory duties correctly with sponsors, importers and c0
C1-T6Determine competence needs for work affecting quality, close gaps, check effectiveness in proportion to risk, keep competence records and qualify consultants0
C1-T7Top management commits to and owns risk management planning across the product life cycle, with documented methods, acceptability criteria and post-market updating of risk files0
C1-T8Control documents and records of internal and external origin, and keep records and an obsolete copy of documents for at least the device lifetime (minimum two years) or the longer0
C1-T9Conduct documented management reviews at planned intervals covering the suitability and effectiveness of the policy, objectives and QMS against all regulatory requirements0
C2-T1Register facilities and list or license devices as each jurisdiction requires, and (for Australia) compile and maintain the manufacturer's Declaration of Conformity0
C2-T2Hold the marketing clearance or approval each jurisdiction requires before commercial distribution (ANVISA registration or notification, Canadian licence, Japanese approval, FDA 510
C2-T3-AUIdentify changes needing regulatory notification and, for Australia, notify the MDSAP auditing organisation (and the TGA for conformity assessment certificate holders) before subst0
C2-T3-BR-CA-JPSubmit significant changes to ANVISA, Health Canada licence amendments and annual statements, and Japanese change applications through the marketing authorization holder0
C2-T3-USFor the United States, update registration and listing, file new 510(k)s or PMA supplements for significant changes, and keep changes within any agreed predetermined change control0
C3-T1Establish documented measurement, analysis and improvement procedures covering monitoring of product conformity, early-warning feedback, CAPA and dissemination of quality problem i0
C3-T10Run planned internal audits under a documented procedure with trained, independent auditors, and follow up findings with corrections, corrective actions and verification0
C3-T11Feed nonconforming product, QMS nonconformity, correction, corrective and preventive action information into management review0
C3-T12Gather and evaluate post-production experience, including complaints and post-market surveillance, feed it into improvement and risk management, and (for Australia) pass serious pr0
C3-T12-BR-USKeep complaint handling procedures and records that meet ANVISA and FDA rules: a designated unit, documented decisions not to investigate, mandatory investigation of failures and r0
C3-T12-CAFor Canada, keep problem and complaint records, run effective investigation and recall procedures, prepare periodic summary reports with critical benefit-risk analysis and notify t0
C3-T12-CYBERFor devices with software or programmable logic, collect cybersecurity feedback (vulnerability reports, incidents, threat intelligence) after release and feed it into risk manageme0
C3-T13Exchange relevant information with external organisations whose activities contributed to a complaint, and keep records of it0
C3-T14-T15Evaluate every complaint for adverse event reportability and every quality problem in distributed product for an advisory notice, under documented procedures with recorded rational0
C3-T2Identify and analyse all relevant quality data sources under a documented procedure, using valid statistical methods where appropriate0
C3-T3-T4Investigate the root causes of nonconformities and potential nonconformities where possible, with depth proportionate to the risk0
C3-T5Determine, implement, document and verify corrections, corrective actions and preventive actions in proportion to risk, without adverse effect on finished devices0
C3-T6-T7Evaluate new hazards and risks from CAPA-driven design or process changes, revalidate processes where needed, and notify regulators, auditing organisations or MAHs of significant o0
C3-T8-T9Identify and control nonconforming product to prevent use or delivery, justify and record dispositions, notify responsible external parties, and act in proportion to risk when nonc0
C4-T1-AUAustralia: report adverse events and near adverse events to the TGA or the Australian sponsor as soon as practicable through the post-marketing system0
C4-T1-BRBrazil: run an integrated post-market surveillance system with a designated responsible professional, record and investigate complaints, and notify ANVISA of adverse events, techni0
C4-T1-CACanada: make preliminary incident reports within 10 days (death or serious deterioration) or 30 days (could recur and cause it), follow with final reports, and report foreign serio0
C4-T1-JPJapan: as a Registered Manufacturing Site, pass serious and specified events, foreign safety actions and study findings to the marketing authorization holder promptly0
C4-T1-USUnited States: maintain written MDR procedures and event files, report deaths, serious injuries and reportable malfunctions within 30 calendar days, 5-day reports where remedial ac0
C4-T2-AUAustralia: tell the TGA or the sponsor as soon as practicable when the manufacturer proposes to recall devices distributed in Australia, with the technical or medical reasons0
C4-T2-BRBrazil: define when field actions are needed, keep records of all field actions, carry them out on evidence of non-compliance or on ANVISA's demand, and notify ANVISA within the se0
C4-T2-CACanada: give Health Canada recall information within 24 hours of the decision, a full written section 64 report within three business days, and a results report after completion0
C4-T2-JPJapan: as a Registered Manufacturing Site, maintain effective communication with the marketing authorization holder on advisory notices so the holder can report them0
C4-T2-USUnited States: report corrections and removals made to reduce a risk to health or remedy a violation within 10 working days, with device identifiers, and keep records of unreported0
C5-T1Identify which devices are subject to design and development controls in each jurisdiction and maintain the technical documentation evidence they require0
C5-T10-T11Validate the design for the intended use with testing scaled to risk, and perform the clinical evaluation or safety and performance evaluation each jurisdiction requires0
C5-T12Develop device software under design controls and risk management0
C5-T12-USUnited States: for cyber devices cleared or approved after 29 March 2023, maintain a postmarket vulnerability plan with coordinated disclosure, cybersecure design and update proces0
C5-T13Control design changes (verify or validate and approve before implementation, assess new risks), notify regulators or the MAH where required, and assign new UDI-DIs for new version0
C5-T14-T15Hold design reviews at planned stages with the right functions and specialists, and review design changes for their effect on product already made and delivered0
C5-T16Transfer the design correctly to production, releasing it only after authorised review of the complete design history0
C5-T3-T4Plan and control each design and development project, with stages, reviews, verification, validation, transfer, responsibilities and interfaces, under established procedures0
C5-T5-T6Establish, review and approve complete, unambiguous, non-conflicting design inputs covering function, performance, safety, intended use, regulations (including Essential Principles0
C5-T7Make design outputs traceable to and satisfy inputs, identify the outputs essential for proper functioning, and verify the design0
C5-T8-T9Apply risk management throughout design with defined acceptability criteria, evaluate and communicate residual risk, and confirm through verification or validation that risk contro0
C6-T1Plan product realization with the controls, controlled conditions and risk management needed to meet intended use and regulatory requirements, consistent with the rest of the QMS a0
C6-T1-UDIDetermine UDI applicability and implement UDI allocation, carriers and data management for Australia (TGA-recognised issuing agency) and the United States (FDA-accredited agency an0
C6-T10-T11Monitor and measure product conformity to a risk-based extent, and operate production within specified limits with production risk controls implemented, monitored and evaluated0
C6-T12Ensure production personnel are competent to carry out and maintain the processes as the organisation requires0
C6-T13-T14Identify, calibrate, adjust and protect monitoring and measuring equipment, and assess and record the validity of earlier results and act on affected product when equipment is foun0
C6-T15Validate software used to control production and service processes, in production equipment or in the QMS for its intended use0
C6-T16Keep a medical device file for each device type with specifications, process, QA, traceability, labelling and packaging and installation and servicing requirements, set traceabilit0
C6-T17Keep a verified, approved batch production record showing quantities made and released, manufacture to the device file and met release requirements, with inspected and controlled l0
C6-T18For implantable, life-supporting or life-sustaining devices, keep traceability of components, materials and environment conditions and inspection personnel, require distributors to0
C6-T19-T20Identify product status so only product that passed inspection is dispatched, used or installed, and identify, verify, protect and safeguard customer property including patient and0
C6-T21Carry out and document acceptance activities for every incoming item and service, to an extent matched to the device risk, with statistically valid sampling for Brazil0
C6-T22-T23Identify, control and dispose of nonconforming product according to risk, and rework only under approved procedures that assess adverse effects, document results and re-verify the 0
C6-T24Preserve product conformity through processing, storage and transport, including identification, handling, packaging, protection, limited shelf life and special storage conditions0
C6-T25Review customer requirements before committing to supply, and keep the distribution records regulators require (consignee, product, quantity, date and control numbers; Canadian ret0
C6-T26-T27Record installation and its verification, perform and document servicing to defined procedures, analyse service records as quality data, and meet ANVISA and FDA service record cont0
C6-T28Apply risk control and mitigation measures to transport, installation and servicing in line with the risk management practice0
C6-T3Run production and service under controlled conditions: product information, procedures and workmanship criteria, suitable equipment, monitoring devices, process and product monito0
C6-T4Set documented product cleanliness requirements (including before sterilisation and for non-sterile supply) and removal of process agents, with pest control and housekeeping for Br0
C6-T5-T6Define and maintain the infrastructure and work environment needed for conformity, including equipment maintenance, personnel health and clothing, environmental monitoring, special0
C6-T7-T8Identify the processes (including outsourced ones) that need validation and validate them under documented procedures, with revalidation after changes and methods reflecting the st0
C6-T9Validate and periodically revalidate sterilisation and sterile barrier processes, manufacture sterile devices under controlled conditions and keep batch-traceable sterilisation rec0
C7-T1-T3Plan purchasing (what to buy and outsource, requirements, records, resources, acceptance and risk management) and document procedures ensuring purchased product meets requirements0
C7-T10-T11Verify purchased product to a risk-appropriate combination of supplier controls, purchase requirements and acceptance, keep verification records, hold material until verified (Braz0
C7-T4-T5Set documented, risk-based criteria for selecting, evaluating and re-evaluating suppliers, select suppliers on their ability to meet requirements, keep evaluation records and quali0
C7-T6-T7Monitor supplier performance, maintain effective controls so requirements continue to be met, and re-evaluate suppliers at intervals matched to the significance of their product0
C7-T8-T9Ensure purchasing information is adequate and documented before release to the supplier, including product, process, personnel and QMS requirements, risk controls, traceability and0
cycleMDSAP audit cycle: initial (stage 1 and 2), surveillance, recertification, special, unannounced and regulator audits0
overviewWhat MDSAP is, the process-based audit sequence and how tasks cite requirements0
selectionAuditor sample selection tasks (design project, production process, supplier file)0

Tell me when MDSAP Audit Approach (MDSAP AU P0002) files something new

One email when a public company newly discloses something this framework governs, naming the company and what our corpus says it puts in scope. Nothing else, and one click to stop.

What this page is

A control-level reference for MDSAP Audit Approach (MDSAP AU P0002), drawn from our framework corpus. Control codes and titles are references to the standard, not reproductions of it. The overlap counts and the auditor artefacts are our own work and are the part you will not find elsewhere.

Measure this against what you already run · All frameworks · Today's edition